Understanding how LINE-1 activity affects fallopian tube cells in ovarian cancer
Official title: Defining the genomic and biologic impact of LINE-1 activity in fallopian tube epithelial cells
Funded at Massachusetts General Hospital · NIH-11102148 · Data updated 2026-11-12
This study is looking at how a specific genetic element called LINE-1 might play a role in the development of high-grade serous ovarian cancer, focusing on its activity in cells from the fallopian tubes, to help find better ways to understand and treat this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 16, 2025 |
| Project end | April 30, 2030 |
| Funding year | 2025 |
| Award (this year) | $744,575 |
| NIH project number | 1R01CA299969-01 |
| Project ID | NIH-11102148 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include women at high risk for ovarian cancer, particularly those with BRCA1 mutations or a family history of the disease.
✕Less likely to help
Patients with non-gynecological cancers or those without a family history of ovarian cancer may not benefit from this research.
What this research studies
This research investigates the role of LINE-1, a type of genetic element, in the development of high-grade serous ovarian cancer (HGSOC) by examining its activity in fallopian tube epithelial cells. The study aims to understand how LINE-1 contributes to the formation of pre-cancerous lesions and their progression to cancer. By analyzing the genetic changes and biological effects of LINE-1, researchers hope to uncover new insights into ovarian cancer development. Patients may benefit from this research through improved understanding of cancer mechanisms and potential new therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to better prevention strategies and treatments for ovarian cancer.
How similar studies have gone: Previous research has shown that understanding genetic elements like LINE-1 can provide valuable insights into cancer biology, suggesting potential for success in this area.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Rueda, Bo R. — Massachusetts General Hospital
- Study coordinator: Rueda, Bo R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.